Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.52 |
| ▸ | PEPD | P12955 | 2/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.45 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CMA1 | P23946 | 8/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28186217 | 0.91 | KLK5 (0.52) | KLK5PEPDACEXPNPEP1FKBP1A | |
| SCHEMBL22070276 | 0.89 | ACE (0.57) | KLK5PEPDACEF2PRSS1 | |
| SCHEMBL22070275 | 0.89 | ACE (0.57) | KLK5PEPDACEF2PRSS1 | |
| SCHEMBL30483497 | 0.88 | ACE (0.43) | KLK5ACEFKBP1AF2PRSS1 | |
| SCHEMBL18630366 | 0.87 | KLK5 (0.49) | KLK5PEPDACEXPNPEP1FKBP1A | |
| SCHEMBL21536111 | 0.86 | CTSK (0.53) | KLK5PEPDACEXPNPEP1FKBP1A | |
| SCHEMBL28286258 | 0.86 | CTSK (0.53) | KLK5PEPDACEXPNPEP1FKBP1A | |
| SCHEMBL8254962 | 0.86 | CTSK (0.50) | KLK5PEPDACEXPNPEP1FKBP1A | |
| SCHEMBL10144067 | 0.85 | TSHR (0.52) | KLK5PEPDACEXPNPEP1FKBP1A | |
| SCHEMBL7311829 | 0.85 | KLK5 (0.53) | KLK5PEPDACEXPNPEP1FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| EP-4121055-A1 | STAT DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | KLK5 892/4885PEPD 64/4885ACE 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.